Emergent BioSolutions secures $250M contracts for the U.S. government

Emergent BioSolutions ( NYSE: EBS ) received more than $250M in contract modifications from the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures ((MCMs)). The contracts includes: $30M modification to supply CYFENDUS this year; $99.9M modification to supply ACAM2000 and two new contract options totaling $122.

9M. These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threats and emergencies against anthrax, smallpox and botulism. The stock price gained 3.



4% on Tuesday during pre-market trade. More on Emergent Biosolutions Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround Emergent BioSolutions Inc. (EBS) Q1 2024 Earnings Call Transcript Emergent BioSolutions Inc.

2024 Q1 - Results - Earnings Call Presentation Emergent to sell Baltimore-Camden production site for $30M Walgreens launches its own opioid reversal therapy for OTC use.